Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Cyteir Therapeutics Nabs $29 Million and a New CEO March 7, 2018 ICON Reports Fourth Quarter And Full Year 2016 Results February 15, 2017 Syndax To Announce First Quarter 2017 Financial Results And Host Conference Call And Webcast On May 8, 2017 April 30, 2017
Syndax To Announce First Quarter 2017 Financial Results And Host Conference Call And Webcast On May 8, 2017 April 30, 2017
